Wellington Management Group LLP Purchases Shares of 105,018 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Wellington Management Group LLP bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 105,018 shares of the company's stock, valued at approximately $692,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of RXRX. Allspring Global Investments Holdings LLC purchased a new stake in Recursion Pharmaceuticals in the 3rd quarter worth about $25,000. Farther Finance Advisors LLC boosted its position in Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after purchasing an additional 4,091 shares during the period. KBC Group NV increased its stake in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. Amalgamated Bank raised its position in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after purchasing an additional 2,459 shares during the period. Finally, San Luis Wealth Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter valued at approximately $69,000. 89.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Leerink Partners reduced their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research note on Tuesday, September 3rd. Needham & Company LLC reiterated a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Finally, Jefferies Financial Group cut their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research note on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $9.25.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock traded down $0.06 during trading on Friday, hitting $6.03. The stock had a trading volume of 19,762,197 shares, compared to its average volume of 6,733,188. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $15.74. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -3.94 and a beta of 0.85. The business's 50-day moving average is $6.76 and its 200 day moving average is $7.20.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the prior year, the company earned ($0.43) earnings per share. Recursion Pharmaceuticals's revenue was up 147.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the firm's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $6.22, for a total transaction of $71,200.34. Following the transaction, the director now directly owns 7,098,428 shares of the company's stock, valued at approximately $44,152,222.16. This trade represents a 0.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Tina Marriott sold 6,000 shares of the business's stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares of the company's stock, valued at $3,647,966. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 107,788 shares of company stock worth $724,691 over the last three months. 15.75% of the stock is owned by insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.